Limits...
A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno.

Senatore C, Charlier B, Truono A, Punzi R, D'Aniello F, Boffa N, Izzo V, Conti V, Russomanno G, Manzo V, Filippelli A, Mazzeo M - Transl Med UniSa (2014)

Bottom Line: Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR.All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLAB*57.01 carriers.In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.

View Article: PubMed Central - PubMed

ABSTRACT
Abacavir is a nucleoside reverse transcriptase inhibitor largely used as part of the antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected patients. Some individuals (2-9%) who start an abacavir treatment show an immunologic reaction indicated as hypersensitivity reaction syndrome (HSR) that is often responsible for therapy discontinuation and could represent a life-threatening event. Some studies demonstrated a correlation between this adverse reaction and the class I of the major histocompatibility complex (MHC) allele, HLA-B*57.01, in several populations, including Caucasians. Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR. Both male and female HIV-infected patients were enrolled at the Infectious Diseases Division at the University Hospital of Salerno, and admitted to a prospective HLAB*57.01 screening. Genetic analysis was carried out through two sequential Real-Time PCR reactions in which Sybr-Green was used. Out of 248 patients, 215 were Italians from Southern Italy and 33 were coming from several non-EU members countries. All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLAB*57.01 carriers. In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.

No MeSH data available.


Related in: MedlinePlus

amplification plots (panels A and C) and the corresponding melting curve (panels B and D)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4309657&req=5

f1-tm-11-55: amplification plots (panels A and C) and the corresponding melting curve (panels B and D)

Mentions: A total of 248 HIV-infected patients (66 women and 182 men) were enrolled and admitted to this prospective HLA-B*57.01 screening for the prevention of ABC-correlated HSR. 215 individuals were Italians from Southern Italy, 33 were non-EU. None of the patients had previously received a treatment with abacavir. HLA-B*57.01 frequency values were similar in both Italians (2.8%) and non-EU (3.0%). In Figure 1 amplification plots (panels A and C) and the corresponding melting curve (panels B and D) were showed.


A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno.

Senatore C, Charlier B, Truono A, Punzi R, D'Aniello F, Boffa N, Izzo V, Conti V, Russomanno G, Manzo V, Filippelli A, Mazzeo M - Transl Med UniSa (2014)

amplification plots (panels A and C) and the corresponding melting curve (panels B and D)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4309657&req=5

f1-tm-11-55: amplification plots (panels A and C) and the corresponding melting curve (panels B and D)
Mentions: A total of 248 HIV-infected patients (66 women and 182 men) were enrolled and admitted to this prospective HLA-B*57.01 screening for the prevention of ABC-correlated HSR. 215 individuals were Italians from Southern Italy, 33 were non-EU. None of the patients had previously received a treatment with abacavir. HLA-B*57.01 frequency values were similar in both Italians (2.8%) and non-EU (3.0%). In Figure 1 amplification plots (panels A and C) and the corresponding melting curve (panels B and D) were showed.

Bottom Line: Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR.All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLAB*57.01 carriers.In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.

View Article: PubMed Central - PubMed

ABSTRACT
Abacavir is a nucleoside reverse transcriptase inhibitor largely used as part of the antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected patients. Some individuals (2-9%) who start an abacavir treatment show an immunologic reaction indicated as hypersensitivity reaction syndrome (HSR) that is often responsible for therapy discontinuation and could represent a life-threatening event. Some studies demonstrated a correlation between this adverse reaction and the class I of the major histocompatibility complex (MHC) allele, HLA-B*57.01, in several populations, including Caucasians. Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR. Both male and female HIV-infected patients were enrolled at the Infectious Diseases Division at the University Hospital of Salerno, and admitted to a prospective HLAB*57.01 screening. Genetic analysis was carried out through two sequential Real-Time PCR reactions in which Sybr-Green was used. Out of 248 patients, 215 were Italians from Southern Italy and 33 were coming from several non-EU members countries. All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLAB*57.01 carriers. In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.

No MeSH data available.


Related in: MedlinePlus